CMP.AX stock up 38.46% to A$0.45 at ASX close: Volume spike merits watch
CMP.AX stock led ASX gainers on 23 Jan 2026, finishing at A$0.45, up 38.46% on heavy volume of 695,750 shares. The jump outran the 50-day average price of A$0.35 and pushed price above recent trading ranges. Investors pointed to improved quarterly flows and renewed demand for sleep and neurology diagnostic equipment as immediate drivers. We examine the drivers, financials, technicals and Meyka AI forecasts to frame what the move means for holders and traders in Australia.
CMP.AX stock: intraday move and trading flow
Compumedics Limited (CMP.AX) closed at A$0.45 on the ASX with a single-day gain of 38.46% and volume of 695,750, almost nine times the average volume of 82,155. The stock opened at A$0.37, hit a day high of A$0.45 and day low of A$0.37, signalling aggressive intraday buying. The heavy volume suggests institutional or concentrated retail interest rather than algorithmic noise.
CMP.AX stock: financial snapshot and valuation
Compumedics shows a market capitalisation of A$72.91m, EPS of -0.01 and a reported PE of -36.50, reflecting near-term losses. Key valuation metrics: price-to-sales 1.43, price-to-book 2.98, and current ratio 1.10, indicating modest liquidity. Gross profit margin is 60.71%, but interest coverage at 0.56 and net income per share of -0.0071 highlight ongoing profitability pressure.
CMP.AX stock: technical picture and momentum
Technically, CMP.AX stock shows mixed signals with RSI at 43.15, ADX 18.21 (no clear trend) and MACD near neutral. The 50-day average is A$0.3519 and 200-day average A$0.3121, both below the close, giving short-term bullish context. Price broke higher with a widening gap in volume, though momentum oscillators like Stochastic (%K 11.90) remain weak, so follow-through is needed to confirm a sustained rally.
Meyka AI rating and CMP.AX stock forecast
Meyka AI rates CMP.AX with a score out of 100: 61.90 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 and sector comparisons, financial growth, key metrics and analyst consensus. Meyka AI’s forecast model projects monthly A$0.28, quarterly A$0.34, yearly A$0.3856, 3-year A$0.4588, 5-year A$0.5313 and 7-year A$0.6044. Compared with the current price A$0.45, the model shows implied moves from -37.78% (monthly) to +34.32% (7-year). Forecasts are model-based projections and not guarantees.
CMP.AX stock: catalysts, risks and sector context
Near-term catalysts include the next earnings announcement on 3 Mar 2026 and order updates for sleep and neurology systems in Asia and the Americas. Major risks are thin free cash flow (FCF yield 0.64%), interest coverage constraints and customer receivable days at 106. Within the ASX Healthcare and Medical – Devices sector, Compumedics sits smaller than peers and must execute on sales growth to lift margins and reduce leverage.
CMP.AX stock: analyst view and price targets
Independent rating data shows a recent company rating of C- with a recommendation of Strong Sell dated 22 Jan 2026, signalling divergence between market buying and some metric-based screens. Realistic near-term price targets anchored to model outputs are A$0.34 (quarter) and A$0.386 (12 months), while a successful execution scenario supports a A$0.53 five-year target. Analysts stress monitoring margins, order conversion and working capital.
Final Thoughts
CMP.AX stock’s 38.46% surge to A$0.45 on 23 Jan 2026 was volume led and meaningful for a small-cap ASX healthcare name. The move put price above the 50- and 200-day averages, but momentum indicators are mixed and fundamental ratios show modest liquidity and negative EPS. Meyka AI rates CMP.AX 61.90 (B, HOLD) and projects a 12-month model price of A$0.3856 (implied -14.30% vs today) while multi-year forecasts show upside to A$0.4588 (3 years, +2.0%) and A$0.5313 (5 years, +18.07%). Traders should treat today’s gain as a signal to monitor earnings on 3 Mar 2026, order flow and receivables conversion before adding exposure. For those looking at risk-adjusted entry, a staged buy with stops below A$0.37 and attention to cashflow metrics is consistent with the stock’s liquidity and sector peers. Meyka AI-powered market analysis suggests watching execution over headlines before shifting a HOLD view to BUY.
FAQs
What drove the CMP.AX stock surge on 23 Jan 2026?
CMP.AX stock rose on heavy volume of 695,750 shares and positive trading flow. Reports of stronger order interest in sleep and neurology diagnostics, plus technical breakouts above the 50-day average, likely triggered buying.
What is Meyka AI’s outlook for CMP.AX stock?
Meyka AI’s forecast model projects A$0.3856 in 12 months and longer-term gains to A$0.5313 in five years. These are model-based projections and not guarantees of future returns.
Should investors buy CMP.AX stock after the rally?
Investors should weigh the rally against weak EPS (negative) and limited cash per share. A staged approach is prudent: monitor the 3 March 2026 earnings update and cashflow trends before increasing exposure.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
